These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22641321)

  • 1. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2012 Jun; 16(3):286-91. PubMed ID: 22641321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
    Sartor O; Halstead M; Katz L
    Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
    Pouessel D; Oudard S; Gravis G; Priou F; Shen L; Culine S
    Bull Cancer; 2012; 99(7-8):731-41. PubMed ID: 22743148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peg-filgrastim and cabazitaxel in prostate cancer patients.
    Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
    Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Oudard S
    Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manage side effects of cabazitaxel in patients with castrate-resistant prostate cancer.
    Becze E
    ONS Connect; 2012 Sep; 27(9):16-7. PubMed ID: 23008908
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
    Mita AC; Figlin R; Mita MM
    Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
    Keating GM
    Drugs Aging; 2013 May; 30(5):359-65. PubMed ID: 23532557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel in metastatic castration-resistant prostate cancer.
    Yap TA; Pezaro CJ; de Bono JS
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
    Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
    Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
    Pal SK; Twardowski P; Sartor O
    Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.